What chronic diseases does Zilucoplan mainly treat?

Zilucoplan (Zilucoplan) is a small molecule inhibitor that targets complement C5 protein. It was originally designed to treat a type of chronic autoimmune diseases caused by excessive activation of the complement system. The core indication is acetylcholine receptor antibody-positive (AChR-Ab+) myasthenia gravis (MG; rare disease), which is a chronic, progressive, potentially life-threatening neuromuscular disease. Its pathological basis is antibody-mediated neuromuscular junction dysfunction. Zeleptide fundamentally prevents the progression of myasthenia by blocking terminal complement activation and preventing immune complexes from attacking neuromuscular connections.

In addition to myasthenia gravis, zeleptide is also being studied in several other diseases closely related to complement activation, such as paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), and certain types of neuromyelitis optica spectrum disorder (NMOSD). Although these indications have not yet been fully approved, some early clinical studies have shown that the drug's mechanism of action in these diseases is also valid, providing a theoretical basis for its future expansion of indications.

It is worth noting that compared with traditional immunosuppressive treatments, such as glucocorticoids, immunoglobulins or macromolecular antibody drugs (such aseculizumab), the biggest advantage of zeleptide is its small molecule design and subcutaneous injection form, which facilitates patients to self-administer at home, reducing hospital dependence and infusion costs. At the same time, the drug takes effect quickly, has stable blood concentration, and is more efficient in controlling symptoms.

Therefore, although the main indications of Zeleptide are currently focused on myasthenia gravis, its core mechanism of action is applicable to a variety of chronic autoimmune diseases whose pathological basis is excessive activation of the terminal complement system. In the future, there is still much room for application and expansion in the field of rare disease treatment, especially in chronic neurological diseases, renal diseases and hematopoietic system diseases related to the complement pathway. Its potential deserves continued attention.

Reference materials:https://www.drugs.com/zilucoplan.html